Atossa Therapeutics, Inc

(NASDAQ:ATOS)

Latest On Atossa Therapeutics, Inc (ATOS):

Date/Time Type Description Signal Details
2023-03-22 23:50 ESTNewsAtossa Therapeutics GAAP EPS of -$0.21 beats by $0.01N/A
2023-02-28 16:56 ESTNewsAtossa Therapeutics FY 2022 Earnings PreviewN/A
2023-02-13 17:16 ESTNewsAtossa announces new U.S. patent covering lead assetN/A
2022-11-08 08:22 ESTNewsAtossa Therapeutics GAAP EPS of -$0.06 in-lineN/A
2022-11-01 22:41 ESTNewsAtossa acquiring ~20% stake in Dynamic Cell Therapies to boost CAR-T developmentN/A
2022-10-24 18:54 ESTNewsAtossa receives FDA OK to begin phase 2 trial of (Z)-endoxifen for breast cancerN/A
2022-10-11 12:37 ESTNewsAtossa Therapeutics: Still Gets An 'Incomplete' RatingN/A
2022-08-08 19:55 ESTNewsAtossa Therapeutics GAAP EPS of -$0.05N/A
2022-06-06 16:58 ESTNewsClover Health, Aurinia Pharma among the top 10 health care additions to Russell 3000 Index, Asensus Surgical, Clovis Oncology among top deletionsN/A
2022-05-10 02:23 ESTNewsAtossa Therapeutics GAAP EPS of -$0.04 beats by $0.02N/A
2022-04-21 01:18 ESTNewsAtossa rebounds after enrollment update on study for COVID-19 therapyN/A
2022-03-09 03:27 ESTNewsAtossa Therapeutics issued patent covering breast cancer therapy endoxifenN/A
2022-03-01 03:13 ESTNewsAtossa Therapeutics GAAP EPS of -$0.18N/A
2021-12-10 10:39 ESTNewsA First Assessment On Atossa TherapeuticsN/A
2021-11-15 21:01 ESTNewsAtossa Therapeutics EPS beats by $0.02N/A
2021-10-01 08:19 ESTNewsAtossa starts enrollment in early-stage trial for COVID-19 therapy targeting long-haulersN/A
2021-09-22 21:41 ESTNewsAtossa Therapeutics: Diversification Into COVID Makes Sense In A Variants WorldN/A
2021-09-02 15:07 ESTNewsAtossa Therapeutics gets approval for mid-stage Endoxifen MBD trial in SwedenN/A
2021-08-14 05:43 ESTNewsAtossa Therapeutics EPS misses by $0.02N/A
2021-07-31 05:09 ESTNewsAtossa falls 10% after convening a special meeting for shareholdersN/A
2021-07-31 05:09 ESTNewsERYTECH Pharma, Allied Healthcare Products leads healthcare gainers; Intec Pharma, Translate Bio among major losersN/A
2021-07-30 09:56 ESTNewsAtossa loses a tenth after convening a special meeting for shareholdersN/A
2021-07-20 19:59 ESTNewsAtossa reaches a two-year high ahead of data readout for breast cancer therapyN/A
2021-07-20 19:58 ESTNewsAtossa Therapeutics shares fall after mid-stage Endoxifen breast cancer study resultsN/A
2021-07-20 19:55 ESTNewsAtossa Therapeutics to be included in the Russell 2000, 3000 indexesN/A
2021-07-20 19:51 ESTNewsAtossa Therapeutics continues rally amid a series of catalystsN/A
2021-07-20 19:45 ESTNewsQuant System Highlight: Investors Following This Are Up 120% In A Month! (Video)N/A
2021-07-20 19:44 ESTNewsAtossa rallies ahead of inclusion in Russell IndexesN/A
2021-07-20 19:43 ESTNewsArcus Bio ranks in top weekly healthcare gainers amid positive domvanalimab data; Biogen hit by Lilly donanemab Breakthrough Therapy tagN/A
2021-07-20 19:39 ESTNewsAtossa Therapeutics: Hope Springs EternalN/A
2021-07-20 19:36 ESTNewsCassava, Annovis among H1 biotech winners while Grayburg, Odonate biggest laggardsN/A
2021-07-20 19:33 ESTNewsAtossa Therapeutics gets regulatory nod for AT-H201 COVID-19 study in AustraliaN/A
2021-07-20 19:27 ESTNewsAtossa Therapeutics: Bear Market Defying Biotech Running Out Of UpsideN/A
2021-07-20 19:26 ESTNewsAtossa in selloff for second straight session after sharp run-up this yearN/A
2021-07-20 19:26 ESTNewsFreeline Therapeutics, Cytokinetics leads healthcare gainers; China SXT Pharmaceuticals, Atossa Therapeutics among major losersN/A
2021-04-17 03:15 ESTNewsAtossa Therapeutics Finds Its Share Price Drifting Between CatalystsN/A
2021-04-09 00:34 ESTNewsAtossa Therapeutics says ovarian cancer patient begins treatment with oral endoxifenN/A
2021-03-31 17:04 ESTNewsAtossa Therapeutics EPS misses by $0.76N/A
2021-03-22 22:55 ESTNewsAtossa Therapeutics prices $50M direct offering; shares fallN/A
2021-03-11 23:43 ESTNewsAtossa gets FDA safe to proceed letter for endoxifen in an ovarian cancer patientN/A
2021-02-25 20:05 ESTNewsAtossa climbs after announcing early-stage data for COVID-19 nasal sprayN/A
2021-02-11 03:16 ESTNewsAtossa hints at potential pipeline additions, provides 2021 strategyN/A
2021-02-10 07:12 ESTNewsZomedica, Nemaura and Senseonics extend premarket gainsN/A
2021-02-06 14:45 ESTNewsAssessing Atossa TherapeuticsN/A
2021-02-04 09:55 ESTNewsAtossa updates on single-patient study for EndoxifenN/A
2021-02-02 22:07 ESTNewsAtossa halts Endoxifen breast cancer study after positive dataN/A
2021-01-06 17:26 ESTNewsAtossa Therapeutics prices ~$25M direct offering, stock -23% PMN/A
2021-01-02 15:09 ESTFinancialsCompany financials have been released.Neutral
2020-12-17 13:49 ESTNewsAtossa Therapeutics prices $14M registered direct offeringN/A
2020-12-13 03:15 ESTFinancialsCompany financials have been released.Neutral

About Atossa Therapeutics, Inc (ATOS):

Atossa Therapeutics, Inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States. The company's lead program is the development of Endoxifen, an active metabolite of tamoxifen which is in Phase II studies to treat and prevent breast cancer. It is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and Chimeric Antigen Receptor T-cell therapies, directly to the site of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2009 and is headquartered in Seattle, Washington.

ATOS Quotes by TradingView

See Advanced Chart

General

  • Name Atossa Therapeutics, Inc
  • Symbol ATOS
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 4
  • Last Split Factor1:12
  • Last Split Date2018-04-20
  • Fiscal Year EndDecember
  • IPO Date2012-11-08
  • Gic SectorHealth Care
  • Gic GroupHealth Care Equipment & Services
  • Gic IndustryHealth Care Equipment & Supplies
  • Gic SubIndustryHealth Care Equipment
  • Web URLhttp://atossatherapeutics.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 21.03
  • Enterprise Value EBITDA 0.09
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Next Quarter EPS Estimate -$0.36
  • Return on Assets -58%
  • Return on Equity -104%
  • Earnings Per Share -$2.51
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 193.97 million
  • EBITDA -16713626
  • Analyst Target Price $6.25
  • Book Value Per Share $0.88
View More

Share Statistics

  • Shares Outstanding 71.57 million
  • Shares Float 9.37 million
  • % Held by Insiders 12%
  • % Held by Institutions 6.49%
  • Shares Short 7.06 million
  • Shares Short Prior Month 5.76 million
  • Short Ratio 0.21
  • Short % of Float 10%
  • Short % of Shares Outstanding 10%
View More

Technicals

  • Beta 2.16
  • 52 Week High $5.08
  • 52 Week Low $0.81
  • 50 Day Moving Average 2.95
  • 200 Day Moving Average 2.01
View More

Dividends

  • Dividend Date 2018-04-20
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Atossa Therapeutics, Inc (ATOS) Dividend Calendar:

ATOS's last dividend payment was made to shareholders on April 20, 2018.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Atossa Therapeutics, Inc (ATOS) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-13$N/A-$0.34-$0.351.45%
2020-06-302020-08-13$N/A-$0.43-$0.28-53.57%
2020-03-312020-05-13$N/A-$0.32-$0.3917.95%
2019-12-312020-03-26$N/A-$0.26-$0.3321.21%
2019-09-302019-11-13$N/A-$0.36-$0.5230.77%
2019-06-302019-08-13$N/A-$0.80-$0.48-66.67%
2019-03-312019-05-13$N/A-$0.62
2018-12-312019-03-28$N/A-$1.25-$0.63-100%
2018-09-302018-11-13$N/A-$0.64-$0.57-13.27%
2018-06-302018-08-13$N/A-$2.90-$0.56-422.52%
2018-03-312018-05-14$N/A-$0.71-$0.8617.44%
2017-12-312018-03-08$N/A$2.28-$0.84371.43%
2017-09-302017-11-13$N/A-$1.99-$3.4842.86%
2017-06-302017-08-14$N/A-$7.17-$5.28-35.73%
2017-03-312017-05-11$N/A-$5.40
2016-12-312017-03-16$N/A-$12.96-$10.92-18.68%
2016-09-302016-11-14$N/A$0.84-$15.36105.47%
2016-06-302016-08-12$N/A-$9.00-$12.6028.57%
2016-03-312016-05-05$N/A-$13.30
2015-12-312016-03-30$-5337911-$10.80-$27.0060%
2015-09-302015-11-12$772244-$27.02
2015-06-302015-08-06$2.69 million-$20.45
2015-03-312015-05-13$1.87 million-$24.09
2014-09-302014-11-12$3426-$23.81
2014-06-302014-08-12$10000-$23.49
2014-03-312014-05-14$24000-$18.00-$19.809.09%
2013-12-312014-03-27$48000-$27.00-$34.2021.05%
2013-09-302013-11-12$76000-$39.60-$22.50-76%
2013-06-302013-08-14$327000-$30.60-$25.20-21.43%
2013-03-312013-05-15$182000-$25.20-$18.00-40%
2012-12-312013-03-28$99000-$19.80-$19.800%
2012-09-302012-12-20$105000-$18.28

Atossa Therapeutics, Inc (ATOS) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Atossa Therapeutics, Inc (ATOS) Chart:

Atossa Therapeutics, Inc (ATOS) News:

Below you will find a list of latest news for Atossa Therapeutics, Inc (ATOS) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Atossa Therapeutics, Inc (ATOS) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2026-06-1810CALL0 00TRUE00
2026-06-1820CALL0 00TRUE00
2026-06-1830CALL0 0126.15TRUE00
2026-06-1840CALL0 0130.67TRUE00
2026-06-1850.42CALL0 4135.92TRUE00
2026-06-1860.11CALL0 17154.31FALSE00
2026-06-1870.15CALL0 61237.8FALSE00
2026-06-1880.1CALL0 6159.63FALSE00
2026-06-1890CALL0 1306.69FALSE00
2026-06-18100.07CALL0 122182.01FALSE00
2026-06-1810.37PUT1 1903.27FALSE0.370
2026-06-1820.4PUT1 0524.62FALSE0.40
2026-06-1830.01PUT0 60192.39FALSE00
2026-06-1840.2PUT0 4210.62FALSE00
2026-06-1850.6PUT0 1105.16FALSE00
2026-06-1860PUT0 0128.45TRUE00
2026-06-1870PUT0 0133.02TRUE00
2026-06-1880PUT0 0167.87TRUE00
2026-06-1890PUT0 0196.64TRUE00
2026-06-18100PUT0 0221.23TRUE00
2026-07-170.50.2CALL0 1010TRUE00
2026-07-1714.25CALL0 30TRUE00
2026-07-171.50.05CALL0 3280TRUE00
2026-07-1720CALL0 0192.74TRUE00
2026-07-1730CALL0 1117.92TRUE00
2026-07-1740CALL0 177.26TRUE00
2026-07-1750.67CALL5 21110.12TRUE0.670
2026-07-1760.45CALL0 9107.43FALSE00
2026-07-1770.2CALL0 30143.97FALSE00
2026-07-1780.45CALL0 29169.26FALSE00
2026-07-1790CALL0 1189.87FALSE00
2026-07-17100CALL0 3207.27FALSE00
2026-07-170.50.27PUT0 500FALSE00
2026-07-1710PUT0 0550.15FALSE00
2026-07-171.50PUT0 00FALSE00
2026-07-1720PUT0 0319.71FALSE00
2026-07-1730PUT0 2117.45FALSE00
2026-07-1740PUT0 5147.15FALSE00
2026-07-1750.7PUT0 6121.83FALSE00
2026-07-1760PUT0 194.47TRUE00
2026-07-1770PUT0 0111.06TRUE00
2026-07-1780PUT0 0126.12TRUE00
2026-07-1790PUT0 0145.5TRUE00
2026-07-17100PUT0 0139.02TRUE00
2026-10-1610CALL0 0186.24TRUE00
2026-10-1620CALL0 12137.35TRUE00
2026-10-1632.75CALL0 1110TRUE00
2026-10-1640CALL0 0108.95TRUE00
2026-10-1651.15CALL0 9100.05TRUE00
2026-10-1660.88CALL0 1595.22FALSE00
2026-10-1670.78CALL6 3394.88FALSE0.780
2026-10-1680.45CALL0 1494.91FALSE00
2026-10-1690.49CALL0 5397.43FALSE00
2026-10-1610PUT0 0320.62FALSE00
2026-10-1620PUT0 0207.69FALSE00
2026-10-1630PUT0 0146.26FALSE00
2026-10-1640.6PUT0 11104.97FALSE00
2026-10-1650PUT0 31101.97FALSE00
2026-10-1660PUT0 297.75TRUE00
2026-10-1672.45PUT0 1598.07TRUE00
2026-10-1682.7PUT0 1105.4TRUE00
2026-10-1690PUT0 0109.28TRUE00
2027-01-1510CALL0 0181.44TRUE00
2027-01-1520CALL0 0140.77TRUE00
2027-01-1530CALL0 0122.59TRUE00
2027-01-1540CALL0 0119.51TRUE00
2027-01-1550CALL0 0103.36TRUE00
2027-01-1560CALL0 097.81FALSE00
2027-01-1571.1CALL0 2894.53FALSE00
2027-01-1580CALL0 094.04FALSE00
2027-01-1590.62CALL0 194.01FALSE00
2027-01-15100CALL0 086.24FALSE00
2027-01-1510PUT0 0283.63FALSE00
2027-01-1520PUT0 0166.31FALSE00
2027-01-1530PUT0 0136.21FALSE00
2027-01-1540PUT0 0119.17FALSE00
2027-01-1550PUT0 0111.31FALSE00
2027-01-1560PUT0 0106.14TRUE00
2027-01-1570PUT0 097.29TRUE00
2027-01-1580PUT0 091.16TRUE00
2027-01-1590PUT0 088.07TRUE00
2027-01-15100PUT0 089.35TRUE00

Latest ATOS Trades:

Date Shares Price
Jun 13, 2022 7:57 PM EST180$1.055
Jun 13, 2022 7:58 PM EST100$1.055
Jun 13, 2022 7:59 PM EST100$1.055
Jun 13, 2022 7:59 PM EST100$1.055
Jun 13, 2022 7:59 PM EST100$1.055

Atossa Therapeutics, Inc (ATOS) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-05-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000143774920011265/0001437749-20-011265-index.htm
2018-04-06UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1488039/000000000018010515/0000000000-18-010515-index.htm
2018-04-25UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1488039/000000000018012803/0000000000-18-012803-index.htm
2018-06-12UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1488039/000000000018018066/0000000000-18-018066-index.htm
2020-09-08UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1488039/000000000020008409/0000000000-20-008409-index.htm
2017-10-31SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1488039/000090266417004121/0000902664-17-004121-index.htm
2018-01-19SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1488039/000090266418000311/0000902664-18-000311-index.htm
2017-11-09SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1488039/000093041317003736/0000930413-17-003736-index.htm
2018-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1488039/000093041318000510/0000930413-18-000510-index.htm
2018-04-27SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1488039/000121390018005062/0001213900-18-005062-index.htm
2019-02-08SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1488039/000121390019001898/0001213900-19-001898-index.htm
2018-11-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774918020569/0001437749-18-020569-index.htm
2018-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1488039/000143774918020638/0001437749-18-020638-index.htm
2019-01-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774919000870/0001437749-19-000870-index.htm
2019-03-2810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1488039/000143774919005927/0001437749-19-005927-index.htm
2019-03-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774919005929/0001437749-19-005929-index.htm
2019-04-12DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1488039/000143774919007053/0001437749-19-007053-index.htm
2019-05-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774919009664/0001437749-19-009664-index.htm
2019-05-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1488039/000143774919009666/0001437749-19-009666-index.htm
2019-05-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774919010399/0001437749-19-010399-index.htm
2019-05-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000143774919010644/0001437749-19-010644-index.htm
2019-05-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000143774919010645/0001437749-19-010645-index.htm
2019-05-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000143774919010646/0001437749-19-010646-index.htm
2019-05-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000143774919010647/0001437749-19-010647-index.htm
2019-05-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000143774919010648/0001437749-19-010648-index.htm
2019-06-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774919012879/0001437749-19-012879-index.htm
2019-08-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1488039/000143774919016448/0001437749-19-016448-index.htm
2019-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774919016451/0001437749-19-016451-index.htm
2019-10-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774919020029/0001437749-19-020029-index.htm
2019-11-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1488039/000143774919022613/0001437749-19-022613-index.htm
2019-11-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774919022614/0001437749-19-022614-index.htm
2020-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774920000245/0001437749-20-000245-index.htm
2020-02-07424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1488039/000143774920002083/0001437749-20-002083-index.htm
2020-02-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774920002085/0001437749-20-002085-index.htm
2020-03-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774920006154/0001437749-20-006154-index.htm
2020-03-2610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1488039/000143774920006155/0001437749-20-006155-index.htm
2020-04-13DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1488039/000143774920007556/0001437749-20-007556-index.htm
2020-04-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774920007600/0001437749-20-007600-index.htm
2020-04-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000143774920007628/0001437749-20-007628-index.htm
2020-04-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000143774920007630/0001437749-20-007630-index.htm
2020-05-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774920010512/0001437749-20-010512-index.htm
2020-05-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1488039/000143774920010514/0001437749-20-010514-index.htm
2020-05-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774920011257/0001437749-20-011257-index.htm
2020-05-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000143774920011261/0001437749-20-011261-index.htm
2020-05-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000143774920011262/0001437749-20-011262-index.htm
2020-05-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000143774920011263/0001437749-20-011263-index.htm
2020-05-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000143774920011264/0001437749-20-011264-index.htm
2020-05-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000143774920011265/0001437749-20-011265-index.htm
2020-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774920017737/0001437749-20-017737-index.htm
2020-08-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1488039/000143774920017738/0001437749-20-017738-index.htm
2020-09-02S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1488039/000143774920019223/0001437749-20-019223-index.htm
2020-09-08CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1488039/000143774920019381/0001437749-20-019381-index.htm
2020-09-25424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1488039/000143774920020266/0001437749-20-020266-index.htm
2020-09-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000143774920020267/0001437749-20-020267-index.htm
2017-11-03SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1488039/000155335017001165/0001553350-17-001165-index.htm
2017-11-03SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1488039/000155335017001167/0001553350-17-001167-index.htm
2017-10-26424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1488039/000161577417005904/0001615774-17-005904-index.htm
2017-10-27424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1488039/000161577417005964/0001615774-17-005964-index.htm
2017-10-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000161577417005989/0001615774-17-005989-index.htm
2017-11-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1488039/000161577417006519/0001615774-17-006519-index.htm
2017-11-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000161577417006627/0001615774-17-006627-index.htm
2017-11-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000161577417006777/0001615774-17-006777-index.htm
2017-12-21424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1488039/000161577417007507/0001615774-17-007507-index.htm
2017-12-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000161577417007555/0001615774-17-007555-index.htm
2018-02-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000161577418000770/0001615774-18-000770-index.htm
2018-02-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000161577418001342/0001615774-18-001342-index.htm
2018-03-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000161577418001692/0001615774-18-001692-index.htm
2018-03-0810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1488039/000161577418001693/0001615774-18-001693-index.htm
2018-03-08PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1488039/000161577418001705/0001615774-18-001705-index.htm
2018-03-20DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1488039/000161577418001985/0001615774-18-001985-index.htm
2018-03-27S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1488039/000161577418002120/0001615774-18-002120-index.htm
2018-04-02DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1488039/000161577418002285/0001615774-18-002285-index.htm
2018-04-16DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1488039/000161577418002644/0001615774-18-002644-index.htm
2018-04-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000161577418002666/0001615774-18-002666-index.htm
2018-04-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000161577418002808/0001615774-18-002808-index.htm
2018-04-23S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1488039/000161577418002813/0001615774-18-002813-index.htm
2018-04-23CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1488039/000161577418002815/0001615774-18-002815-index.htm
2018-05-03S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1488039/000161577418003227/0001615774-18-003227-index.htm
2018-05-03CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1488039/000161577418003229/0001615774-18-003229-index.htm
2018-05-07CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1488039/000161577418003390/0001615774-18-003390-index.htm
2018-05-07CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1488039/000161577418003391/0001615774-18-003391-index.htm
2018-05-10424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1488039/000161577418003583/0001615774-18-003583-index.htm
2018-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1488039/000161577418003668/0001615774-18-003668-index.htm
2018-05-16FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/1488039/000161577418003930/0001615774-18-003930-index.htm
2018-05-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000161577418003978/0001615774-18-003978-index.htm
2018-05-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000161577418004587/0001615774-18-004587-index.htm
2018-05-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000161577418004655/0001615774-18-004655-index.htm
2018-05-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000161577418004657/0001615774-18-004657-index.htm
2018-05-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000161577418004659/0001615774-18-004659-index.htm
2018-06-04S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1488039/000161577418004829/0001615774-18-004829-index.htm
2018-06-12CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1488039/000161577418005158/0001615774-18-005158-index.htm
2018-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000161577418005994/0001615774-18-005994-index.htm
2018-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000161577418005995/0001615774-18-005995-index.htm
2018-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000161577418005996/0001615774-18-005996-index.htm
2018-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000161577418005997/0001615774-18-005997-index.htm
2018-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000161577418005998/0001615774-18-005998-index.htm
2018-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000161577418006000/0001615774-18-006000-index.htm
2018-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000161577418006001/0001615774-18-006001-index.htm
2018-07-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000161577418006119/0001615774-18-006119-index.htm
2018-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000161577418007922/0001615774-18-007922-index.htm
2018-08-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1488039/000161577418007923/0001615774-18-007923-index.htm
2018-09-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1488039/000161577418009490/0001615774-18-009490-index.htm
2018-11-1310-Q/AQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1488039/000161577418012549/0001615774-18-012549-index.htm
2019-01-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000161577419000644/0001615774-19-000644-index.htm
2019-01-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1488039/000161577419000645/0001615774-19-000645-index.htm
2018-05-09EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1488039/999999999518001185/9999999995-18-001185-index.htm
2018-06-14EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1488039/999999999518001509/9999999995-18-001509-index.htm
2020-09-10EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1488039/999999999520002415/9999999995-20-002415-index.htm

Atossa Therapeutics, Inc (ATOS) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Atossa Therapeutics, Inc (ATOS). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 12%
Institutional Ownership: 649%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2017-11-15Kyle GuseCFO, Gen Counsel and SecretaryBuy1,400.000.34471.1010,000.00https://www.sec.gov/Archives/edgar/data/1488039/000161577417006777/0001615774-17-006777-index.htm
2017-11-15Kyle GuseCFO, Gen Counsel and SecretaryBuy8,600.000.342,898.208,600.00https://www.sec.gov/Archives/edgar/data/1488039/000161577417006777/0001615774-17-006777-index.htm